NasdaqGS:REGNBiotechs
Assessing Regeneron Pharmaceuticals (REGN) Valuation After Recent Weak Share Momentum And Franchise Outlook
Recent performance context
Regeneron Pharmaceuticals (REGN) has recently drawn investor attention after a period of weaker share performance, with the stock showing negative returns over the past week, month and past 3 months despite a positive 1 year total return.
See our latest analysis for Regeneron Pharmaceuticals.
The recent 6% 1 month share price decline and slightly negative year to date share price return contrast with an 11.9% 1 year total shareholder return. This suggests that...